Stephen Golden, MD
Family Medicine · Jonesboro, ARNPI 1093778169
Payments from drug & device makers
Across 370 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$924
- AstraZeneca$852
- AbbVie$722
- Novo Nordisk$702
- GSK$587
- Amgen$282
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,681100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 65 | $924 |
| AstraZeneca | 42 | $852 |
| AbbVie(2 entities) | 40 | $722 |
| Novo Nordisk | 49 | $702 |
| GSK | 42 | $587 |
| Amgen | 21 | $282 |
| Lilly USA, LLC | 17 | $263 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $194 |
| Boehringer Ingelheim | 8 | $121 |
| Abbott | 7 | $116 |
| E.r. Squibb & Sons, L.L.C. | 7 | $106 |
| Merck | 8 | $98 |
| Otsuka America Pharmaceutical, Inc. | 4 | $83 |
| Astellas Pharma US Inc | 6 | $75 |
| Bayer | 5 | $74 |
| Novartis | 5 | $64 |
| Phathom Pharmaceuticals, Inc. | 5 | $50 |
| Shire North American Group Inc | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $40 |
| Dexcom, Inc. | 2 | $32 |
| Edwards Lifesciences | 1 | $30 |
| Amarin Pharma, Inc. | 2 | $26 |
| Mylan Specialty L.p. | 2 | $23 |
| Eisai Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Nalpropion Pharmaceuticals LLC | 1 | $11 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| Corium, LLC | 1 | $10 |
How this compares
$5,687 in reported general payments places this provider in the 85th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 82 | $57,714 |
| JardianceEmpagliflozin | 59 | $56,287 |
| OzempicSemaglutide | 45 | $44,807 |
| MounjaroTirzepatide | 29 | $29,709 |
| JanuviaSitagliptin Phosphate | 22 | $20,001 |
| FarxigaDapagliflozin Propanediol | 26 | $18,578 |
| Chlorpromazine Hcl | 12 | $16,204 |
| TrulicityDulaglutide | 14 | $15,967 |
| XareltoRivaroxaban | 18 | $14,479 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $13,173 |
| LinzessLinaclotide | 19 | $9,594 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,386 |
| Potassium Chloride | 230 | $5,456 |
| JentaduetoLinagliptin/Metformin Hcl | 11 | $5,413 |
| MyrbetriqMirabegron | 12 | $5,074 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat, Jentadueto | $121 | $68,08683 claims |
| PfizerEliquis, Premarin | $924 | $59,91394 claims |
| Lilly USA, LLCMounjaro, Trulicity | $263 | $45,67643 claims |
| Novo NordiskOzempic | $702 | $44,80745 claims |
| MerckJanuvia | $98 | $20,00122 claims |
| AstraZenecaFarxiga | $852 | $18,57826 claims |
| Johnson & JohnsonXarelto | $13 | $14,47918 claims |
| GSKTrelegy Ellipta | $587 | $13,17321 claims |
| AbbVieLinzess | $722 | $9,59419 claims |
| Astellas Pharma US IncMyrbetriq | $75 | $5,07412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Jonesboro
- Christopher BrownJonesboro$160K
- Wallace HokeJonesboro$16K
- Timothy ShownJonesboro$14K
- Randall CarltonJonesboro$13K
- Trent LambJonesboro$13K
- Jeffery BarberJonesboro$12K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.